drugset / Trial / NCT01302795
Canakinumab for Pyoderma Gangrenosum
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.
Timeline
- Start
- 2011-02
- Primary completion
- 2014-08
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 150 mg | Subcutaneous |